THC Prolonged Barbiturate Hypnosis Without Increasing Acute Hypnotic Tolerance

Longer drug-induced hypnosis did not necessarily produce more acute tolerance in a historical animal experiment. The study abstract reports that THC prolonged pentobarbital hypnosis without enhancing the development of acute hypnotic tolerance.

The experiment separated duration from adaptation

Kaneto and Nagaoka investigated whether the initial brain concentration of pentobarbital or the duration of hypnosis determined later tolerance. Their abstract describes several pharmacological manipulations rather than treating time asleep as a direct measurement of tolerance. It reports that bemegride and thyrotropin-releasing hormone shortened the hypnotic effect without changing pentobarbital brain levels or tolerance development.

THC changed one outcome without changing the other

THC significantly prolonged pentobarbital-induced hypnosis but did not potentiate the development of acute tolerance. The authors interpreted their combined findings as favoring initial brain pentobarbital concentration over hypnosis duration as the relevant determinant in this experimental setting. The supplied abstract does not provide the THC dose, group sizes or a precise numerical increase in hypnosis duration; those details cannot be assigned to the result.

The conclusion concerns a particular animal model

This was preclinical pharmacology, not a trial of cannabis users undergoing human anesthesia. Drug-induced hypnosis in the experiment should not be treated as equivalent to ordinary sleep, a driving-performance measure or a clinical anesthetic requirement. The result also does not establish that combining cannabis and a barbiturate is safe. It demonstrates why an interaction that extends an acute drug effect and an adaptation that reduces a later response require separate evidence. One cannot substitute the duration of the first response for a measured tolerance outcome.

Related analysis: a separate study of temperature tolerance and prolonged pentobarbital sleep.

Research cited

Kaneto and Nagaoka (1981). Further studies on the determinant role of brain level of pentobarbital for the development of acute hypnotic tolerance. Abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication

The final trial reported that efficacy results for cycles B and C were not analyzed because of substantial crossover. The first-cycle benefit therefore should not be presented as three separately demonstrated cycles of efficacy. Later treatment histories became mixed The study included different continuation and crossover arrangements across its phases….

Spread the love

Read Article: Later Chemotherapy Cycles Did Not Supply an Analyzed Efficacy Replication

Self-Titration Produced Different Capsule Counts in Active and Placebo Chemotherapy Arms

The chemotherapy study permitted capsule adjustment according to nausea and side effects. Active and placebo participants consequently did not take the same median number of capsules per dose. Capsule content and regimen were specified Each active capsule contained 2.5 milligrams of THC and 2.5 milligrams of CBD. Treatment was scheduled…

Spread the love

Read Article: Self-Titration Produced Different Capsule Counts in Active and Placebo Chemotherapy Arms

Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views

The chemotherapy trial collected both patient-rated cannabinoid-related symptoms and clinician-graded adverse events. Their percentages should not be combined as though they used one severity definition. The assessments used different frameworks Participants completed a structured checklist including sedation, dizziness, anxiety, disorientation, hallucinations and palpitations. Clinicians used the Common Terminology Criteria for…

Spread the love

Read Article: Patient-Rated Cannabis Symptoms and Clinician-Graded Adverse Events Gave Different Safety Views

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us